AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02269384 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Experimental Noxious Stimulus
Description: Localized manual pressure will be placed up predetermined points on the lower extremity until maximum pain tolerance levels are reached.
Study NCT02269384 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Memory of Experimental Noxious Stimulus
Description: Subjects will be asked to visualize previously experience experimental noxious stimulus
Study NCT03692780 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Careseng 1370
Description: 4,000mg granules in sachet
Study NCT03692780 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 4,000mg granules in sachet
Study NCT04680520 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Experimental (Doublebase Gel® or Diprobase Cream®)
Description: Emollient (Doublebase Gel® or Diprobase Cream®) use on the skin. The emollient should be applied at least once a day.
Study NCT04680520 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Best practice skin care advice booklet
Description: This is a booklet containing advice on best practice skin care. This will contain information on avoiding soap etc.
Study NCT04680520 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Best practice skin care advice booklet
Description: This is a booklet containing advice on best practice skin care. This will contain information on avoiding soap etc.
Study NCT01522924 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Counseling practice sessions
Description: Dental students will complete the first questionnaire before a tobacco cessation lecture and the second questionnaire after the lecture, counseling practice sessions using standardized patients and a debriefing session.
Study NCT01700296 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Best care
Description: Best Care: subjects are randomly assigned to the Best care regardless MRC class and severity of symptoms through:~1. 10 weeks of rehabilitation (2 hours, 2 times a week) by Region Zealand's instructions on sundhed.dk. COPD rehabilitation includes physical exercise, smoking cessation, medication, nutrition education and psychosocial support and patient education. Rehabilitation provided by a multidisciplinary effort with lung nurse, dietician and physiotherapist according to national and international guidelines (1.5) (6) (24) (25)~2. Outpatient follow-up every 3 months, a total of 5 visits, and during these visits various subjective, clinical, paraclinical and invasive parameters.
Study NCT02269384 — intervention group
Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Memory of Experimental Noxious Stimulus
Description: Subjects will be asked to visualize previously experience experimental noxious stimulus
Study NCT03306368 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Youth Opioid Recovery Support
Description: The components of the Youth Opioid Recovery Support intervention are:~XR-NTX, home delivery of XR-NTX, the family framework approach engages and empowers families, assertive continuing care incorporates outreach, home delivery of XR-NTX, contingency management.
Study NCT00959361 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: pharmaceutical care
Description: consultation with the pharmacists and usual care
Study NCT01551888 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aclidinium/formoterol 400/12μg
Description: Aclidinium/formoterol 400/12μg fixed dose combination (FDC), one inhalation twice daily (morning and evening) for 4 days, then one inhalation (morning) on Day 5 via the Almirall inhaler
Study NCT02269384 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Memory of Prior Significant Injury
Description: Subjects will visual prior significant injury or a predetermined lower extremity region in control subjects.
Study NCT02269384 — intervention group
Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Memory of Prior Significant Injury
Description: Subjects will visual prior significant injury or a predetermined lower extremity region in control subjects.
Study NCT02269384 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Mental Challenge Test
Description: Subjects will count backwards from 100 by specified amounts as rapidly as possible
Study NCT02269384 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Mental Challenge Test
Description: Subjects will count backwards from 100 by specified amounts as rapidly as possible
Study NCT03027193 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ChAdOx2 HAV
Description: The ChAdOx2 HAV vaccine consists of the replication-deficient simian adenovirus vector ChAdOx2, containing the Mycobacterium avium subspecies paratuberculosis (MAP) antigens
Study NCT03027193 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MVA HAV
Description: The MVA HAV vaccine consists of the replication deficient modified vaccinia virus Ankara (MVA) containing the Mycobacterium avium subspecies paratuberculosis (MAP) antigens.
Study NCT01551888 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Formoterol
Description: Formoterol 12 μg one inhalation twice daily (morning and evening) for 4 days, then one inhalation (morning) on Day 5 via the Foradil® Aerolizer®
Study NCT04360044 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: THC ~5%
Description: 4 puffs of vaporized flower containing THC \~5%
Study NCT04360044 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CBD ~12%
Description: 4 puffs of vaporized flower containing CBD \~12%
Study NCT04360044 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: THC ~5% and CBD ~12%
Description: 4 puffs of vaporized flower containing THC \~5% and CBD \~12%
Study NCT04360044 — intervention group
Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Sham Cannabis
Description: 4 puffs of vaporized flower from which the THC and CBD have been extracted
Study NCT03321162 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: scan protocol
Description: Scanning strategy is based on multiple scans. Essentially one CT scan of the patient (usually with a scan appliance). Another CT scan of the model or scan appliance may be required (double scan technique). Such a second CT scan can be replaced by optical scanning of the model and scan appliance (triple scan technique).
Study NCT03525158 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Brief cognitive intervention
Description: A one-session intervention with a researcher including a simple cognitive task (a memory cue, 10 minutes time gap and ca. 20 minutes of Tetris game play) with instructions to engage in the task self-guided in the subsequent week.
Study NCT01062737 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASU
Study NCT02641197 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AngioDefender
Description: Repeatability will be assessed by repeat AngioDefender (AD) testing of the same subject 1 hour apart, using the same AD device and operator.~Reproducibility will be assessed by comparing FMD scores obtained for the same subject, but using different AD devices and operators.
Study NCT02788682 — intervention group
Intervention type: GENETIC
Intervention: WT+ Diplotype
Description: 3 or 4 vitamin D binding protein major alleles
Study NCT03127644 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sodium Zirconium Cyclosilicate (ZS) 5g
Description: Suspension administered 5g orally three times daily for 48 hours.
Study NCT03127644 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sodium Zirconium Cyclosilicate (ZS) 10g
Description: Suspension administered 10g orally three times daily for 48 hours.
Study NCT03127644 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo suspension administered orally placebo three times daily for 48 hours.
Study NCT01058460 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: HPV-cytology co-testing
Description: Subjects will receive HPV testing and conventional cytology testing at baseline. Follow up management will be based on both results.
Study NCT03576183 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: VLA1701
Description: VLA1701 is an investigational oral vaccine against LT-ETEC (Labile Toxin-Enterotoxigenic E coli)
Study NCT03576183 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: buffer component of VLA1701
Study NCT03576183 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Challenge Strain
Description: LSN03-016011/A
Study NCT03576183 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Challenge Strain
Description: LSN03-016011/A
Study NCT03891186 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Metacognitive Training in Schizophrenia (MCT)
Description: MCT is a group program with eight modules referring to common cognitive and biases in solving problems in schizophrenia. The following topics of MCT are: attribution blaming and taking credit (module 1), jumping to conclusions (modules 2 and 7), changing beliefs (module 3), deficits in theory of mind and social cognition (modules 4 and 6), overconfidence in (memory) errors (module 5) and depression and low self-esteem (module 8). Each session lasts 45 to 60 minutes and follows a protocol defined in the manual Metacognitive Training for Psychosis (MCT) that is currently available in 35 languages (available in www.uke.de/mkt).
Study NCT03891186 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Treatment As Usual (TAU)
Description: In both groups will be maintained the TAU.
Study NCT03891186 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Treatment As Usual (TAU)
Description: In both groups will be maintained the TAU.
Study NCT02317718 — intervention group
Intervention type: OTHER
Intervention: monitor reproductive outcome
Study NCT06285045 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Roujin Formula
Description: 48 eligible participants with FMS of blood deficiency and liver depression syndrome were selected and randomly divided into treatment group(n=24)and control group(n=24). The treatment group was given Roujin Foumula 150mL,twice a day; The control group was given Roujin Foumula placebo 150mL,twice a day,the study period was 8 weeks. The evaluation points were 0 weeks,4 weeks,and 8 weeks of treatment,and follow-up to 12 weeks. To evaluate the effect changes before and after treatment,FIQR score、VAS score、PSQI score、BDI score and SF-36 PCS、MCS score were used as secondary efficacy evaluation indexes. SPSS23.0 was used to analyze the data.
Study NCT01724229 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Kendall Body Wash & Shampoo; Moisture Barrier Cream; 2-in-1 Cleanser; Antifungal Cream
Study NCT01668160 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bead placement during revision hip replacement surgery
Description: Tantalum beads will be placed in the surrounding pelvic and femoral bone and the polyethylene component during surgical treatment of failed primary THA components
Study NCT04324788 — intervention group
Intervention type: OTHER
Intervention: Group 1
Description: The patients will be asked to go up and down 9-step stair with the highest speed they can make.
Study NCT04324788 — intervention group
Intervention type: OTHER
Intervention: Group 2
Description: The patients will be asked to go up and down 9-step stair with the highest speed they can make.
Study NCT01373918 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intralipid
Description: The subject will receive 1 g/kg/d of the standard intravenous fat emulsion while receiving Parenteral Nutrition until discharge from the hospital, death or 100 days of life, whichever comes first.
Study NCT01373918 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intralipid
Description: The subject will receive 3 g/kg/d of the standard intravenous fat emulsion while receiving Parenteral Nutrition until discharge from the hospital, death or 100 days of life, whichever comes first.
Study NCT02970396 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: self-management
Study NCT04834141 — intervention group
Intervention type: OTHER
Intervention: FlexiCurve ruler method to assess thoracic kyphosis angle
Description: The determination that the effect of thoracic kyphosis posture on trunk biomechanical alignment may be related to balance may contribute to new treatment recommendations in this area. The aim of this study is to investigate whether the thoracic kyphosis posture has an effect on static balance.
Study NCT00746343 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: IRRI
Description: Subjects will remain in their assigned treatment condition for 24 months. IRRI subjects will meet with the lifestyle coach 25-27 times throughout the duration of the study.
Study NCT00746343 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PCCM
Description: Subjects will remain in their assigned treatment condition for 24 months.
Study NCT00224445 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Truvada
Description: Truvada (emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg tablet) administered orally once daily (QD)
Study NCT00224445 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atazanavir
Description: Atazanavir 300 mg (given as two 150-mg capsules) administered orally QD
Study NCT03425877 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Rest
Description: At this stage, the HR and GSR signals will be recorded during a period of rest of 10 minutes. The subjects wear a pair of headphone for reducing the environmental sound noise. Through the headphones a sound indicates to the subject when recording starts and stops. Two separate recording of 5 minutes are performed, the first is performed while keeping eyes closed The two session are presented randomly to each different subject in order to prevent a bias due to order effect .
Study NCT02248038 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: open surgery
Description: Patients in this arm undergo radical resection of colon cancer in open surgery.Open surgery is a conventional technique for colorectal cancer patients.
Study NCT02248038 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: laparoscopic surgery
Description: Patients in this arm undergo radical resection of colon cancer in laparoscopic surgery.Laparoscopic surgery is a new and minimum invasive technique for colorectal cancer patients.
Study NCT04174976 — intervention group
Intervention type: PROCEDURE
Intervention: wall hernia repair
Description: Wall hernia repair with mesh
Study NCT03776097 — intervention group
Intervention type: OTHER
Intervention: observational study
Description: Observational study
Study NCT04432285 — intervention group
Intervention type: DEVICE
Intervention: DBS-device, implanted in GPi bilaterally
Description: Chronic/continuous bilateral GPi-DBS
Study NCT04432285 — intervention group
Intervention type: DRUG
Intervention: Botulinum toxin
Description: Repeated intramuscular injections at regular intervals of around 3 months
Study NCT00476554 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sapacitabine
Description: Sapacitabine
Study NCT03317886 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: pancreaticoduodenectomy
Description: pancreaticoduodenectomy for pancreatic ductal adenocarcinoma
Study NCT03513315 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Implementation of Community-based Home Heat Bundle
Description: This community-based intervention include a set of educational materials to increase awareness about heat-related illness and prevention with the intention of reducing the incidence of heat-related and reducing mortality associated with heat-related illness. Materials used in this intervention will include posters, brochures, in-person training, and SMS messaging.
Study NCT01970215 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TA-8995
Study NCT00422981 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: AL-108
Description: 5 mg QD
Study NCT00422981 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: AL-108
Description: 15 mg BID
Study NCT01970215 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: TA-8995
Study NCT00422981 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT01682863 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: QVA149
Description: QVA149 will be supplied in a capsule form in blister packs for use in the Novartis Concept1 SDDPI
Study NCT01682863 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: QAB149
Description: QAB149 and matching placebo will be supplied in capsule form in blister packs for use in the Novartis Concept1 SDDPI
Study NCT01682863 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: To mimic QAB149
Study NCT03080415 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Combined Therapy SOF and DCV
Description: 1 whole or half tablet sofosbuvir and 1 whole or half tablet daclatasvir per day~SOF dosage: 400 mg/day for greater than 45 kg weight patients; 200 mg/day for 17 kg to 45 kg patients~DCV dosage: 60 mg/day for greater than 45 kg weight patients; 30 mg for 17 kg to 45 kg patients
Study NCT05854888 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Perineal Massage and Warm Compresses (PeMWaC)
Description: Perineal Massage was performed in the II Hodge Plan, between maternal contractions and regardless of maternal position. Warm Compresses were applied by the midwife between Hodge plans III and IV, during pushing and regardless of maternal position.
Study NCT01970215 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atorvastatin
Study NCT01970215 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rosuvastatin
Study NCT01970215 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: TA-8995 0mg (placebo)
Study NCT01970215 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: TA-8995 0mg (placebo)
Study NCT01970215 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Statin
Study NCT01970215 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo Statin
Study NCT03485339 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: genome testing
Description: blood sampling via venipuncture
Study NCT05854888 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Control Group (Hands-on)
Description: The midwife placed the index, middle, and little fingers of the non-dominant hand together on the child's occiput, with the palm facing the anterior region of the perineum, when the child's head was crowning. In this way, the expulsion was controlled, maintaining the flexion of the head. Simultaneously, the dominant hand was flattened and placed on the posterior region of the perineum, with the index finger and thumb, forming a U, exerting pressure on the posterior region of the perineum during the crowning process. During the birth of the shoulders and the rest of the body, the dominant hand was kept in place, protecting the posterior region of the perineum.
Study NCT01831453 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: omega-3
Description: polyunsaturated fatty acids(PUFAs) 1 gram three times per day for 6 months
Study NCT00865696 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mirtazapine 15 mg tablets, single dose
Description: A: Experimental Subjects received Purepac formulated products under fasting conditions
Study NCT03513315 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Regular Community Healthcare provision
Description: The community will get regular community health workers visit without the focus community mobilization and education on heat-related illnesses.
Study NCT01831453 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: soft gelatinous capsules filled with isopropylmyristate oil
Study NCT01386151 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Keratinocyte Growth factor
Description: KGF will be administered intravenously in a 'collapsed dose' regime of 180ug/kg on day 0 and day 11
Study NCT01386151 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline placebo
Description: Normal (0.9%) saline will be used as a placebo.
Study NCT02757365 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: aspirin
Study NCT00865696 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: REMERON® 15 mg tablets, single dose
Description: B: Active comparator Subjects received Organon Inc. formulated products under fasting conditions
Study NCT03045315 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: IVF Procedure
Study NCT02757365 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levofloxacin
Study NCT00288054 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: cetuximab
Description: Cohorts 1 and 2: 400 mg/m2 (initial dose) 2 hour IV infusion on Day 1, Cycle 1 only.~250 mg/m2, 1 hour IV infusion on Days 8 , 15 and 22 during Cycle 1. 250 mg/m2 (subsequent doses), 1 hour IV infusion on Days 1, 8 , 15 and 22 during subsequent cycles.
Study NCT00469209 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Trisenox (Arsenic Trioxide)
Description: 0.25 mg/kg by vein over 2 hours, once a day for 7 days (Days -9 to -3).
Study NCT00469209 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Velcade (Bortezomib)
Description: Arm 1 (Level 1):~1.0 mg/m\^2 intravenous (IV) push on Days -9, -6, and -3. An IV push takes a short period of time (less than 1 minute).~Arm 2 (Level 2):~1.5 mg/m\^2 intravenous (IV) push on Days -9, -6, and -3. An IV push takes a short period of time (less than 1 minute).